GBIM

GlobeImmune, Inc. [GBIM] Stock Forecast

Q: What is GlobeImmune, Inc. stock symbol ?

GlobeImmune, Inc. is a US stock, located in Louisville of Co and trading under the symbol GBIM

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

GBIM Stock Summary

Earnings have grown 8.24% per last year.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

Does not have any significance market cap ($8.05M)

An RSI reading of 30 or below indicates an oversold or undervalued condition.

In the News

GBIM Financial details

Company Rating

Market Cap

8.05M

Income

-2.07M

Revenue

6.21M

Book val./share

0.37

Cash/share

1.51

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

12 May 2016

P/E

Forward P/E

PEG

P/S

7171720.2

P/B

P/C

P/FCF

-1.12

Quick Ratio

2.34

Current Ratio

2.62

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.22

EPS next Y

EPS next Q

EPS this Y

-93.87%

EPS next Y

EPS next 5Y

EPS last 5Y

-68.98%

Revenue last 5Y

4.8%

Revenue Q/Q

-10.04%

EPS Q/Q

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-24%

ROE

-64%

ROC

-0.38%

Gross Margin

100%

Oper. Margin

-43%

Profit Margin

-43%

Payout

Shs Outstand

10.07B

Shs Float

4.37M

Target Price

52W Range

5.0E-4-8.0E-4

52W High

52W Low

RSI

6.29

Rel Volume

Avg Volume

263

Volume

Perf Week

Perf Month

-12.5%

Perf Quarter

Perf Half Y

Beta

-178.922

Volatility

0%, 0%

Prev Close

Price

0.0007

Change

GBIM Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2015-12-31

Metric	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31
Revenue per share	53.42	153.12	235.49	2.05	1.12
Net income per share	-167.22	-0.66	99.11	-7.83	-0.48
Operating cash flow per share	-52.34	-136.66	41.12	-3.45	-1.24
Free cash flow per share	-53.73	-137.8	40.99	-3.55	-1.25
Cash per share	158.48	20.95	61.95	5.77	1.72
Book value per share	-1.91K	-2.05K	-2.08K	1.92	0.52
Tangible book value per share	-1.91K	-2.05K	-2.08K	1.92	0.52
Share holders equity per share	-1.91K	-2.05K	-2.08K	1.92	0.52
Interest debt per share	0	0	-17.85	1.33	0
Market cap	1.06M	1.06M	1.06M	22.12M	22.26M
Enterprise value	-14.1M	-946.32K	-4.67M	5.31M	12.36M
P/E ratio	-0.07	-16.77	0.11	-0.97	-8.04
Price to sales ratio	0.21	0.07	0.05	3.71	3.45
POCF ratio	-0.21	-0.08	0.27	-2.2	-3.12
PFCF ratio	-0.21	-0.08	0.27	-2.14	-3.11
P/B Ratio	-0.01	-0.01	-0.01	3.95	7.45
PTB ratio	-0.01	-0.01	-0.01	3.95	7.45
EV to sales	-2.76	-0.06	-0.21	0.89	1.91
Enterprise value over EBITDA	1.34	0.31	-0.55	-0.96	-4.79
EV to operating cash flow	2.82	0.07	-1.19	-0.53	-1.73
EV to free cash flow	2.74	0.07	-1.19	-0.51	-1.72
Earnings yield	-15.13	-0.06	8.97	-1.03	-0.12
Free cash flow yield	-4.86	-12.47	3.71	-0.47	-0.32
Debt to equity	0	0	0	0	0
Debt to assets	0	0	0.03	0	0
Net debt to EBITDA	1.44	0.66	-0.68	3.04	3.84
Current ratio	1.16	0.35	1.06	3.44	2.62
Interest coverage	0	0	-4.04	-1.5	0
Income quality	0.36	6.49	0.41	0.62	2.58
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0.41	0.14	0.72	0.71
Research and developement to revenue	2.36	0.8	0.48	1.21	0.69
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.03	0.01	0	0.03	0.01
Capex to revenue	-0.03	-0.01	0	-0.05	-0.01
Capex to depreciation	-0.14	-0.12	-0.02	-1	-0.19
Stock based compensation to revenue	0.06	0.03	0.01	0.01	0.02
Graham number	2.68K	174.37	2.16K	18.4	2.37
ROIC	1.06	0.05	-1.23	0.52	0.32
Return on tangible assets	-0.9	-0.01	1.28	-1.24	-0.24
Graham Net	-1.93K	-2.07K	-2.1K	1.39	0.24
Working capital	2.13M	-5.46M	410.64K	12.64M	6.87M
Tangible asset value	-182.4M	-196.12M	-199.32M	5.6M	2.99M
Net current asset value	-184.57M	-197.48M	-199.91M	5.05M	2.57M
Invested capital	0	0	0	0	0
Average receivables	0	0	0	0	0
Average payables	1.22M	2.14M	2.35M	1.15M	403.33K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0.09	0	-0.05	-4.07	-0.93
Capex per share	-1.39	-1.14	-0.13	-0.1	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2016-03-31 for Q1

Metric	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31
Revenue per share	0.21	0.22	0.51	0	0.16
Net income per share	-0.27	-0.23	0.16	0	-0.15
Operating cash flow per share	-0.42	-0.34	-0.23	0	-0.21
Free cash flow per share	-0.43	-0.35	-0.23	0	-0.21
Cash per share	2.5	2.15	1.96	0	1.51
Book value per share	0.71	0.49	0.65	0	0.37
Tangible book value per share	0.71	0.49	0.65	0	0.37
Share holders equity per share	0.71	0.49	0.65	0	0.37
Interest debt per share	0	0	0	0	0
Market cap	42.22M	15.01M	15.01M	0	12.02M
Enterprise value	27.86M	2.65M	3.72M	-9.9M	3.33M
P/E ratio	-6.76	-2.88	4.2	0	-3.49
Price to sales ratio	35.54	11.75	5.1	0	12.75
POCF ratio	-17.36	-7.58	-11.48	0	-9.96
PFCF ratio	-17.19	-7.54	-11.46	0	-9.96
P/B Ratio	10.31	5.29	4	0	5.59
PTB ratio	10.31	5.29	4	0	5.59
EV to sales	23.45	2.07	1.26	-9.45	3.53
Enterprise value over EBITDA	-18.81	-2.14	4.07	12.77	-3.95
EV to operating cash flow	-11.46	-1.34	-2.84	7.03	-2.76
EV to free cash flow	-11.34	-1.33	-2.84	7.03	-2.76
Earnings yield	-0.04	-0.09	0.06	0	-0.07
Free cash flow yield	-0.06	-0.13	-0.09	0	-0.1
Debt to equity	0	0	0	0	0
Debt to assets	0	0	0	0	0
Net debt to EBITDA	9.69	10	-12.36	12.77	10.31
Current ratio	3.27	2.76	2.96	2.62	2.28
Interest coverage	0	0	0	0	0
Income quality	1.56	1.52	-1.46	1.77	1.4
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1	0.92	0.35	1.1	0.99
Research and developement to revenue	1.24	1.04	0.34	0.64	0.9
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.01	0	0	0
Capex to revenue	-0.02	-0.01	0	0	0
Capex to depreciation	-0.3	-0.15	-0.08	0	0
Stock based compensation to revenue	0.04	0.03	0.01	0.03	0.03
Graham number	2.09	1.59	1.51	0	1.12
ROIC	0.11	0.11	-0.09	0.09	0.11
Return on tangible assets	-0.1	-0.1	0.07	-0.07	-0.09
Graham Net	0.52	0.29	0.32	0	0.19
Working capital	10.38M	8.36M	8.53M	6.87M	5.3M
Tangible asset value	4.1M	2.84M	3.75M	2.99M	2.15M
Net current asset value	3.6M	2.39M	3.42M	2.57M	1.83M
Invested capital	0	0	0	0	0
Average receivables	0	0	0	0	0
Average payables	549.57K	615.24K	494.76K	259.83K	320.87K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.38	-0.46	0.24	-0.27	-0.4
Capex per share	0	0	0	0	0

GBIM Frequently Asked Questions

What is GlobeImmune, Inc. stock symbol ?

GlobeImmune, Inc. is a US stock , located in Louisville of Co and trading under the symbol GBIM

What is GlobeImmune, Inc. stock quote today ?

GlobeImmune, Inc. stock price is $0.0007 today.

Is GlobeImmune, Inc. stock public?

Yes, GlobeImmune, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 263
Market Capitalization 8.05M
Employee 2
CEO Mr. C. Jeffrey Dekker CPA
Headquarters Louisville,CO,US
IPO Date 2014-07-02
Website https://www.globeimmune.com

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.